Conservest Capital Advisors Inc. Acquires New Position in Fractyl Health, Inc. (NASDAQ:GUTS)

Conservest Capital Advisors Inc. acquired a new stake in Fractyl Health, Inc. (NASDAQ:GUTS) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 64,118 shares of the company’s stock, valued at approximately $132,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Massachusetts Financial Services Co. MA increased its position in shares of Fractyl Health by 4.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock valued at $2,646,000 after buying an additional 49,289 shares during the period. Geode Capital Management LLC increased its position in shares of Fractyl Health by 166.5% during the third quarter. Geode Capital Management LLC now owns 501,476 shares of the company’s stock valued at $1,269,000 after buying an additional 313,335 shares during the period. State Street Corp increased its position in shares of Fractyl Health by 129.4% during the third quarter. State Street Corp now owns 113,415 shares of the company’s stock valued at $287,000 after buying an additional 63,968 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Fractyl Health by 56.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock valued at $204,000 after buying an additional 29,262 shares during the period. Finally, Barclays PLC increased its position in shares of Fractyl Health by 1,754.7% during the third quarter. Barclays PLC now owns 47,796 shares of the company’s stock valued at $121,000 after buying an additional 45,219 shares during the period.

Fractyl Health Stock Up 6.8 %

GUTS stock opened at $1.56 on Friday. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60. The company’s 50 day moving average is $1.78 and its 200 day moving average is $2.29. The stock has a market cap of $75.03 million and a price-to-earnings ratio of -0.13. Fractyl Health, Inc. has a 1-year low of $1.37 and a 1-year high of $10.50.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley decreased their price target on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd.

Insider Buying and Selling

In related news, insider Jay David Caplan sold 22,346 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $1.81, for a total value of $40,446.26. Following the transaction, the insider now directly owns 153,544 shares in the company, valued at approximately $277,914.64. This represents a 12.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Harith Rajagopalan sold 90,972 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.82, for a total transaction of $165,569.04. Following the completion of the transaction, the chief executive officer now owns 491,329 shares in the company, valued at approximately $894,218.78. This trade represents a 15.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.